Breaking Down Akebia Therapeutics: 4 Analysts Share Their Views

Throughout the last three months, 4 analysts have evaluated Akebia Therapeutics (NASDAQ:AKBA), offering a diverse set of opinions from bullish to bearish.

The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.

	Bullish	Somewhat Bullish	Indifferent	Somewhat Bearish	Bearish
Total Ratings	3	1	0	0	0
Last 30D	1	1	0	0	0
1M Ago	0	0	0	0	0
2M Ago	0	0	0	0	0
3M Ago	2	0	0	0	0

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $5.25, a high estimate of $6.00, and a low estimate of $4.00. This current average has decreased by 8.7% from the previous average price target of $5.75.

Deciphering Analyst Ratings: An In-Depth Analysis

The analysis of recent analyst actions sheds light on the perception of Akebia Therapeutics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst	Analyst Firm	Action Taken	Rating	Current Price Target	Prior Price Target
Allison Bratzel	Piper Sandler	Lowers	Overweight	$4.00	$6.00
Matthew Caufield	HC Wainwright & Co.	Maintains	Buy	$6.00	$6.00
Julian Harrison	BTIG	Maintains	Buy	$5.00	$5.00
Matthew Caufield	HC Wainwright & Co.	Maintains	Buy	$6.00	$6.00

Key Insights:

• Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Akebia Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.
• Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Akebia Therapeutics compared to the broader market.
• Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Akebia Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.

Stay up to date on Akebia Therapeutics analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

All You Need to Know About Akebia Therapeutics

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Financial Milestones: Akebia Therapeutics's Journey

Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.

Positive Revenue Trend: Examining Akebia Therapeutics's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 57.01% as of 30 September, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.

Net Margin: Akebia Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.92% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): Akebia Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.53% ROE, the company effectively utilizes shareholder equity capital.

Return on Assets (ROA): Akebia Therapeutics's ROA excels beyond industry benchmarks, reaching 0.15%. This signifies efficient management of assets and strong financial health.

Debt Management: With a high debt-to-equity ratio of 1.26, Akebia Therapeutics faces challenges in effectively managing its debt levels, indicating potential financial strain.

How Are Analyst Ratings Determined?

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.

This article was generated by Benzinga's automated content engine and reviewed by an editor.